Cargando…
Targeting Toxoplasma gondii ME49 TgAPN2: A Bioinformatics Approach for Antiparasitic Drug Discovery
As fewer therapeutic options are available for treating toxoplasmosis, newer antiparasitic drugs that can block TgAPN2 M1 aminopeptidase are of significant value. Herein, we employed several computer-aided drug-design approaches with the objective of identifying drug molecules from the Asinex librar...
Autor principal: | Altharawi, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10096047/ https://www.ncbi.nlm.nih.gov/pubmed/37049948 http://dx.doi.org/10.3390/molecules28073186 |
Ejemplares similares
-
X-ray crystal structure and specificity of the Toxoplasma gondii ME49 TgAPN2
por: Marijanovic, Emilia M., et al.
Publicado: (2020) -
Evaluating the Antiparasitic Activity of Novel BPZ Derivatives Against Toxoplasma gondii
por: Hatton, Olivia, et al.
Publicado: (2020) -
The detection of Toxoplasma gondii ME49 infections in BALB/c mice using various techniques
por: Kang, Hae-Ji, et al.
Publicado: (2023) -
Identification of potential apicoplast associated therapeutic targets in human and animal pathogen Toxoplasma gondii ME49
por: Saremy, Sadegh, et al.
Publicado: (2011) -
Computational screening of FDA-approved drugs to identify potential TgDHFR, TgPRS, and TgCDPK1 proteins inhibitors against Toxoplasma gondii
por: Gharibi, Zahra, et al.
Publicado: (2023)